Seeking Alpha

Johnson & Johnson (JNJ) says the FDA has approved an 800mg tablet for Prezista, an HIV...

Johnson & Johnson (JNJ) says the FDA has approved an 800mg tablet for Prezista, an HIV treatment for patients with no darunavir resistance-associated mutations. The drug is taken with ritonavir and in combination with other HIV medicines. Prezista is co-developed with Janssen Therapeutics, a division of JNJ owned Janssen Pharmaceutical.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector